Does elevated estrone with high SHBG reflect altered liver estrogen signaling and cholesterol metabolism?

In women undergoing hormonal transitions or oral estrogen therapy, the liver serves as a primary metabolic hub where estrogen receptor-alpha (ERα) signaling coordinates protein synthesis and lipid transport.

Mechanistic regulation of SHBG

• Indirect transcription: While the sex hormone-binding globulin (SHBG) promoter lacks a classical estrogen response element (ERE), hepatic ERα upregulates SHBG by interacting with hepatocyte nuclear factor-4alpha (HNF4α), the primary transcriptional driver of SHBG expression.
• First-pass marker: Oral estrogens undergo extensive first-pass metabolism to estrone (E1). This elevated estrone drives hepatic ERα activation, significantly increasing circulating SHBG. Thus, high SHBG serves as a reliable marker of intensive intrahepatic estrogen exposure, which is bypassed by transdermal routes.

Lipoprotein handling and cholesterol metabolism

• LDL clearance: Hepatic ERα signaling directly enhances low-density lipoprotein (LDL) clearance by stimulating LDL receptor (LDLR) transcription via interaction with Sp1 sites on the LDLR promoter.
• VLDL assembly: Activated ERα induces downstream estrogen-related receptor alpha (ERRα), which upregulates the rate-limiting assembly machinery for VLDL-triglyceride secretion, specifically targeting apolipoprotein B (Apob) and microsomal triglyceride transfer protein (Mttp).
• Clinical lipid shifts: Consequently, altered hepatic signaling manifests as a distinct lipid profile characterized by decreased total and LDL cholesterol, increased HDL cholesterol, and elevated circulating triglycerides.

Bottom line

• Co-elevated estrone and SHBG represent a distinct metabolic signature of intensive hepatic estrogen signaling, reflecting active up-regulation of LDL receptor clearance alongside altered VLDL and triglyceride transport.